Novel semisynthetic derivatives of betulin and betulinic acid with cytotoxic activity by Santos, Rita C. et al.
Bioorganic & Medicinal Chemistry 17 (2009) 6241–6250Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier .com/locate /bmcNovel semisynthetic derivatives of betulin and betulinic acid
with cytotoxic activity
Rita C. Santos a, Jorge A. R. Salvador a,*, Silvia Marín b, Marta Cascante b,*
a Laboratório de Química Farmacêutica, Faculdade de Farmácia, Universidade de Coimbra, Polo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
b IBUB—Department of Biochemistry and Molecular Biology, Faculty of Biology, Universitat de Barcelona, Avda. Diagonal 645, Barcelona 08028, Spain
a r t i c l e i n f o a b s t r a c tArticle history:
Received 23 May 2009
Accepted 22 July 2009
Available online 25 July 2009
Keywords:
Triterpenoids
Betulinic acid
Imidazole
Cytotoxicity0968-0896/$ - see front matter  2009 Elsevier Ltd. A
doi:10.1016/j.bmc.2009.07.050
* Corresponding authors. Tel.: +351 239488479; fa
tel.: +34 93 402 15 9; fax: +34 93 402 12 19 (M.C.).
E-mail addresses: salvador@ci.uc.pt (J.A.R. Salvador
Cascante).A series of new imidazole carboxylic esters (carbamates) and N-acylimidazole derivatives of betulin and
betulinic acid (14–29) have been synthesized. The new compounds were screened for in vitro cytotoxicity
activity against human cancer cell lines HepG2, Jurkat and HeLa. A number of compounds have shown
IC50 values lower than 2 lM against the cancer cell lines tested and the vast majority has shown a better
cytotoxicity profile than betulinic acid, including the betulin derivatives. N-Acylimidazole derivatives 26
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cells) were the most promising compounds. Based on the observed cytotoxicity, structure–activity rela-
tionships have been established.
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301. Introduction
Cancer is the second most important disease leading to death in
both the developing and developed countries nowadays. Numer-
ous experimental and epidemiological studies have shown that
several plant derived natural products may serve as effective anti-
cancer drugs, among which are plant triterpenes, for example bet-
ulin and betulinic acid.1,2 Betulin 1 is a main component of birch
bark,3 and can be synthetically converted to betulinic acid 2 in a
two-step procedure, in high yield.4 Both 1 and 2 (Fig. 1) were re-
ported to display several biological effects including anti-inflam-
matory, antiviral, antimalarial and in particular anticancer.5,6
Previous reports revealed that compound 2 is a melanoma-specific
cytotoxic agent,7 however recent evidence has indicated that 2
possesses a broader spectrum of cytotoxic activity against other
cancer types.8–11 Moreover, compound 2 has been suggested to in-
duce apoptosis via the activation of caspases, regardless of cellular
p53 gene status and CD95 activation.12,13 This apoptosis inducing
ability, the apparent lack of toxicity on normal cells,14 and the
favourable therapeutic index have made 2 an attractive and a very
promising anticancer agent.15
This lupane triterpene is currently undergoing clinical trials at
the National Cancer Institute (NCI).16 Nevertheless, the poor aque-
ous solubility of lupane triterpenes such as 2, which compromises
blood serum solubilization, has limited the exploitation of their po-ll rights reserved.
x: +351 239827126 (J.A.R.S.);
), martacascante@ub.edu (M.tential in both the medical and pharmaceutical areas.17 For this
reason a huge amount of effort has been directed towards perform-
ing modifications of 2 in order to increase and broaden its range of
biological activities. In contrast to 2, compound 1 has no significant
cytotoxic activity.18,19 However, some derivatives were found to be
active.19,20
The structures of 1 and 2 consist of a 30-carbon skeleton which
has three available sites for simple chemical modifications at C-3,
C-20 and C-28. Modifications of the parent structure of these com-
pounds at these positions can produce potentially important deriv-
atives, found to be more effective than the starting ones, thus
making them appealing for further development as antitumour
drugs.18,20–36 Nitrogen-containing derivatives of 1 and 2, such as4 6HO
23 24 Betulin 1: R = CH2OH
Betulinic acid 2: R = COOH
Figure 1. Chemical structure of betulin 1 and betulinic acid 2.
Table 1
Betulin 1 and betulinic acid 2 derivatives 14–21
R2
R1
R2
R1
CDI, THF
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O
6242 R. C. Santos et al. / Bioorg. Med. Chem. 17 (2009) 6241–6250amine derivatives,21,23,35 oxime derivatives,21,23,30 amino acid con-
jugates,22 amide derivatives,20,32 hydrazine29 and hydrazone deriv-
atives,28–30,35 imidazolide derivatives,37 and other N-heterocyclic
derivatives24,31,34,36 have been reported to possess antiproliferative
effect against tumour cell lines.
In the last few years several carbamates have been synthesized
as anticancer agents either in the form of drugs per se or as pro-
drugs. Some carbamates inhibit endothelial cell proliferation
in vitro and tumour induced angiogenesis in vivo as well as tumour
growth in mice.38 Recently, C17 steroidal methylimidazolyl carba-
mates have been reported to possess antiproliferative effects
against prostate cancer cell lines.39
Herein we describe the synthesis and in vitro biological evalua-
tion of novel lupane imidazole carbamates and N-acylimidazole
derivatives, based on the reaction of the commercially available
1,10-carbonyldiimidazole (CDI) with the alcohol and carboxylic
acid functions of compounds 1, 2 and several derivatives. All new
analogs were tested for cytotoxic activity against HepG2 (human
hepatocellular carcinoma), Jurkat (human leukemia) and HeLa (hu-
man cervical adenocarcinoma) cancer cell lines in order to obtain a
preliminary biological profile of this series of compounds that will
be useful for future design and development of other derivatives.401 OH CH2OH 16 O N N
O
CH2OH
2 OH COOH 17
O N N
O
COOH
2 OH COOH 18
O N N
O
N N
O
3 OH CH2OAc 19 O N N
O
CH2OAc
4 OAc CH2OH 20 OAc CH2O N N
O
5 OH COOMe 21
O N N
O
COOMe2. Results and discussion
2.1. Chemistry
The general procedure for the synthesis of the 16 novel lupane
derivatives 14–29 (Table 1, Schemes 1 and 2) involved dissolution
of the corresponding lupanes and CDI, in THF at reflux, under N2.
The reaction of CDI with alcohols and phenols has been reported
to afford either N-alkylimidazoles41–47 or imidazole carboxylic es-
ters (carbamates),39,41,42,48–50 depending both on alcohol type and
on the reaction conditions used. In our case the reaction afforded
the lupane carbamates 14–25 and 29 in good yields. On the other
hand the reaction of CDI with the carboxylic acid function of lu-
pane substrates afforded the N-acylimidazoles 26–28 (Scheme 2)
which was in accordance with previous results.51–53
Due to the fact that the reactivity of the hydroxyl group at C-28
is much higher than that of C-3, the C-28 lupane carbamate 14
could be directly prepared by using mild reaction conditions. In or-
der to synthesize the C-3 lupane carbamate 16, compound 15 was
previously prepared according the general procedure with CDI, and
was then selective hydrolyzed at C-28 with silica gel (Table 1) and
purified by flash column chromatography (FCC) to afford 16, in 68%
yield. For the synthesis of compounds 19 and 20, the correspond-
ing acetylated substrates were prepared (Table 1). Compound 1
was converted into the 28-monoacetate 3 in 78% yield by treat-
ment with acetic anhydride and 2 equiv of imidazole, whereas
the 3-monoacetate 4was prepared by a selective hydrolysis of bet-
ulin diacetate 6 with methanolic potassium hydroxide, in 74%
yield, according to a known procedure.54 Derivative 21 was pre-
pared in 88% yield from methyl ester 5 that was obtained from
the reaction of compound 2 with methyl iodide in the presence
of K2CO3 (Table 1).
The synthesis of derivatives 22 and 23 (Scheme 1) began with
the methoxylation of the isopropenyl group of the commercially
available compound 1 in two steps, as previously described.31 In
the first step the reaction of betulin diacetate 6 with N-bromosuc-
cinimide (NBS) in CCl4 produced a 30-bromo derivative which was
further hydrolyzed by NaOH (4 M) in a MeOH:THF mixture, at
room temperature, to afford the 30-methoxy derivative 7 and the
30-bromo compound 8. The ratio of compounds 7 and 8 was
dependent on the reaction conditions used. An increase in
the hydrolysis time caused an increase in the amount of the30-methoxy derivative 7. This compound was then treated with
CDI in THF, at reflux, to afford 22 and 23 in 68% and 28% yield,
respectively, after FCC. For the synthesis of compounds 24 and
25, previous to the introduction of the carbamate moieties at C-3
and C-28, compound 1 was epoxidized with m-chloroperbenzoic
acid (m-CPBA), followed by acid catalyzed epoxy ring opening to
afford the epimeric isomers (20R-aldehyde) 9 (39%) and (20S-alde-
hyde) 10 (20%) as major products (Scheme 1). The downfield shift
values of the H-20 and H-30 signals on the 1H NMR spectra of com-
pound 9 bearing the 20R configuration (d 9.86 and d 1.10 ppm) and
compound 10 bearing the 20S configuration (d 9.62 and d
1.04 ppm) are characteristic and are consistent with data reported
on the literature.55
For the synthesis of derivative 27, betulonic acid 11 was dehy-
drated with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) in diox-
ane according to the known method (Scheme 2).56 Compound 12
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Scheme 1. Synthesis of derivatives 22–25. Reagents and conditions: (a) NBS, CCl4, reflux, 3 h; (b) NaOH aq (4 N), MeOH, THF, rt, 29 h; (c) CDI, dry THF, N2, reflux, 7–8 h; (d)m-
CPBA, CH2Cl2, 0–5 C, 5 h; (e) H2SO4 (2 M), 0–5 C, 1 h.
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published procedure using oxygen in the presence of potassium
tert-butoxide (t-BuOK) was used for the preparation of the dio-
sphenol 13 as major product (72%).57 Further reaction with CDI
and purification by FCC led to the derivatives 28 and 29, in 70%
and 30% yield, respectively (Scheme 2).
Full structural elucidation of the new lupane derivatives was
made using IR, NMR and MS spectroscopy, and assignments were
performed based on our analysis and related literature. The pres-
ence of a carbamate moiety on the new derivatives 14–25 and 29
was supported by a strong band at 1751–1762 cm1 on the IR
spectrum that corresponded to the C@O stretching vibration. Three
1H NMR peaks at d 8.12–8.29 ppm, d 7.41–7.53 ppm and d 7.05–
7.15 ppm, typical for the imidazole H-2, H-5 and H-4 on the imid-
azole carbamates were found as well as a quaternary 13C NMRsignal at d 147.9–149.1 ppm that was assigned as the carbamate
carbonyl carbon (OCO).42
2.2. Antiproliferative activity
It was been reported that a carbonyl group at position C-17 was
important for the cytotoxic activity of lupane derivatives.25,27 In
the light of this, new lupane imidazole carbamates and N-acylimi-
dazoles with one or two carbonyl groups were synthesized.
To evaluate the anticancer potency of these synthesized com-
pounds, the cytotoxic activity of derivatives 14, 17, 22, 24 and 28
was first screened at concentration of 20 lM against eight human
cancer cell lines of different origin: MCF-7 (breast adenocarci-
noma), HepG2 (hepatocellular carcinoma), A-375 (melanoma),
HT-29 (colon adenocarcinoma), HeLa (cervical adenocarcinoma),
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Scheme 2. Synthesis of derivatives 26–29. Reagents and conditions: (a) CDI, dry THF, N2, reflux, 8–9 h; (b) DDQ, dioxane, N2, reflux, 15 h; (c) O2, t-BuOK, t-BuOH, 40 C, 2 h.
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and Jurkat (leukemia) (Fig. 2). Although compound 2 has been re-
ported to be preferentially effective against melanoma and neuro-
ectodermal tumours, the synthesized derivatives tested in this
study have demonstrated a broad cytotoxicity activity. The per-
centages of cell proliferation as compared to control indicated that
the different compounds were more potent against HepG2, HeLaFigure 2. Screening of antiproliferative activity of synthesized lupane derivatives h 14
different compounds at concentration of 20 lM for 72 h, and cell proliferation was measu
three times.and Jurkat cell lines. These three cancer cell lines were further used
for the determination of the potential of all the new derivatives to
inhibit tumour cell proliferation (Table 2). This potential antitu-
moural effect was tested estimating the concentration at which tu-
mour cell proliferation was inhibited by 50%, after 72 h of
treatment with the compounds. Compound 2 was used as positive
control. As shown in Table 2, analysis of the IC50 values revealed, 17, 22, 24 and j 28 on human cancer cell lines. Cells were treated with
red using MTT or XTT assay. The assay was done using three replicates and repeated
Table 2
Cytotoxic activity data for compounds 14–29 against HepG2, Jurkat and HeLa
Entry Compound IC50a (lM ± SD)
HepG2 Jurkat HeLa
1 2 36.4 ± 1.5 26.9 ± 2.2 26.0 ± 2.1
2 14 4.2 ± 0.3 16.3 ± 1.2 7.6 ± 0.6
3 15 >30 >30 >30
4 16 2.0 ± 0.4 11.1 ± 1.3 3.0 ± 0.2
5 17 6.2 ± 0.2 5.2 ± 0.7 5.1 ± 0.3
6 18 2.9 ± 0.4 6.0 ± 1.2 8.2 ± 0.4
7 19 >30 >30 >30
8 20 >30 >30 >30
9 21 4.3 ± 0.1 9.9 ± 0.6 8.2 ± 0.5
10 22 8.3 ± 0.4 12.2 ± 1.3 9.8 ± 0.6
11 23 19.6 ± 1.6 16.2 ± 1.0 >30
12 24 11.5 ± 1.1 13.7 ± 1.4 11.1 ± 1.4
13 25 26.1 ± 1.1 20.2 ± 1.6 19.2 ± 1.5
14 26 0.8 ± 0.05 1.4 ± 0.2 2.0 ± 0.3
15 27 1.7 ± 0.2 2.3 ± 0.3 3.0 ± 0.2
16 28 6.5 ± 0.4 7.0 ± 1.6 4.6 ± 0.7
17 29 4.0 ± 0.3 8.1 ± 0.6 3.9 ± 0.3
Exponentially growing cells were treated with the compounds at different con-
centrations for 72 h. Cell-growth inhibition was analysed by the MTT (HepG2 and
HeLa) or XTT (Jurkat) assay. The assay was done using three replicates and repeated
four times.
a IC50 is the concentration of compound that inhibits 50% of cell growth.
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tion of all the tested cancer cell lines and were particularly effec-
tive against the hepatoma HepG2 cell line.
The majority of the novel compounds, 14, 16–18 and 21–29,
(Table 2, entries 2, 4–6 and 9–17) showed improved cytotoxic
activity against the three tested tumoural cell lines when com-
pared to compound 2 (Table 2, entry 1), compound 26 being partic-
ularly active (Table 2, entry 14) and 45, 19 and 13-fold more potent
than compound 2 (Table 2, entry 1) towards HepG2, Jurkat and
HeLa cell lines, respectively. The acetyl derivatives 19 and 20 (Ta-
ble 2, entries 7 and 8) and the disubstituted derivative 15 (Table 2,
entry 3) showed higher IC50 values than compound 2 (>30 lM),
which is consistent with the reported data for the in vitro antitu-
mour activity of acetyl derivatives of 1.18 The fact that betulonic
acid derivatives 26 and 27 (Table 2, entries 14 and 15) were the
most active compounds showed that oxidation of the hydroxyl
group to a ketone at C-3 markedly influenced the cytotoxic poten-
tial. The introduction of the carbamate moiety at position C-3 in
compounds 15, 23 and 25 (Table 2, entries 3, 11 and 13) resulted
in a loss of cytotoxicity in all the tested cell lines when compared
with compounds 14, 22 and 24 (Table 2, entries 2, 10 and 12), sug-
gesting a size limitation at position C-3. Moreover, the loss of anti-
proliferative activity of compounds 22 and 23 (Table 2, entries 10
and 11) modified at C-30, and 24 and 25 (Table 2, entries 12 and
13) modified at C-20, indicated that the cytotoxic profile of deriv-
atives of compound 1 may be sensitive to the size and electronic
density of the substituents at C-20, and supports the idea that
the C-20 position of compounds 1 and 2 is not a favourable site
to modify in order to improve antitumoural activity.23
Compounds 18 and 21 (Table 2, entries 6 and 9) inhibited
HepG2 cell proliferation at lower concentrations than compound
17 (Table 2, entry 5), which confirmed that the carbonyl group
and not the carboxyl group was essential for the cytotoxic activity
of the lupane derivatives.25
3. Conclusions
A large number of structural modifications of compounds 1 and
2 as possible antitumour agents were studied. This investigation
demonstrates that the incorporation of an imidazole scaffold atthe C-28 or C-3 position of compounds 1 and 2 to obtain carba-
mates or N-acylimidazoles can produce a number of potentially
important derivatives with improved cytotoxic activity. Modifica-
tions of the less potent compound 1 can lead to derivatives with
a better cytotoxicity profile as shown with derivatives 14, 16, 22
and 24. Compounds 16, 26 and 27 are potential lead compounds
for new anti-tumour agent development and have been selected
for further studies.4. Experimental
4.1. Chemistry
4.1.1. General
Betulin 1, betulinic acid 2, CDI, NBS, NaOH, m-CPBA, H2SO4,
DDQ, t-BuOK and tert-butyl alcohol (t-BuOH) were purchased from
Sigma Aldrich Co., whereas solvents were obtained from VWR Por-
tugal. For thin layer chromatography (TLC) analysis Kieselgel
60HF254/Kieselgel 60G was used and FCC was performed using
Kieselgel 60 (230–400 mesh, Merk). Melting points were deter-
mined using a BUCHI melting point B-540 apparatus and are uncor-
rected. IR spectra were obtained using a JASCO FT/IR-420
spectrophotometer. NMR spectra were recorder on a Bruker Digital
NMR-Avance 300 apparatus and on a Bruker Digital NMR-Avance
400 apparatus in CDCl3withMe4Si as the internal standard. Elucida-
tion of the chemical structureswas basedon 1H, 13C, DEPT135, COSY,
HMQC and HMBC NMR experiments. Chemical shifts values (d) are
given in ppm and the coupling constants (J) are presented in hertz.
Mass spectrawereobtainedusingaFinniganPolarisQGC/MSBench-
top Ion Trap mass spectrometer with a direct insertion probe.
4.1.1.1. 3b-Hydroxylup-20(29)-en-28-yl acetate (3). Details of
the synthesis of this compound were reported previously.54 Com-
pound 3 (323 mg, 84%): IR (film) mmax 3471, 3070, 1734, 1642,
1244, 1102, 880 cm1; 1H NMR (CDCl3, 300 MHz) d 4.69 (s, 1H,
H-29a), 4.59 (s, 1H, H-29b), 4.24 (d, J = 10.9 Hz, 1H, H-28a), 3.86
(d, J = 10.9 Hz, 1H, H-28b), 3.18 (dd, J = 11.0 Hz, J = 4.7 Hz, 1H, H-
3a), 2.45 (dt, J = 10.9 Hz, J = 5.8 Hz, 1H, H-19), 2.07 (s, 3H, OCOCH3),
1.68 (s, 3H, H-30), 1.03 (s, 3H), 0.97 (s, 3H), 0.96 (s, 3H), 0.82 (s,
3H), 0.76 (s, 3H); 13C NMR (CDCl3, 75 MHz) d 171.6 (OCOCH3),
150.2 (C20), 109.9 (C29), 78.9 (C3), 62.8 (C28); EI-MS m/z (% rel.
intensity): 484 (12) M+, 203 (54), 189 (100), 187 (71), 147 (46),
145 (49), 133 (67), 119 (61), 105 (69), 91 (56).
4.1.1.2. 28-Hydroxylup-20(29)-en-3b-yl acetate (4). Details of
the synthesis of this compound were reported previously.54 Com-
pound 4 (259 mg, 89%): IR (film) mmax 3440, 3070, 1729, 1642,
1246, 978, 882 cm1; 1H NMR (CDCl3, 300 MHz) d 4.68 (s, 1H, H-
29a), 4.58 (s, 1H, H-29b), 4.47 (dd, J = 10.3 Hz, J = 5.7 Hz, 1H,
H-3a), 3.79 (d, J = 10.6 Hz, 1H, H-28a), 3.33 (d, J = 10.7 Hz, 1H, H-
28b), 2.39 (dt, J = 10.7 Hz, J = 5.9 Hz, 1H, H-19), 2.04 (s, 3H,
OCOCH3), 1.69 (s, 3H, H-30), 1.02 (s, 3H), 0.97 (s, 3H), 0.85 (s,
6H), 0.84 (s, 3H); 13C NMR (CDCl3, 75 MHz) d 171.1 (OCOCH3),
150.5 (C20), 109.7 (C29), 80.9 (C3), 60.5 (C28); EI-MS m/z (% rel.
intensity): 484 (9) M+, 203 (71), 189 (100), 187 (55), 107 (61),
105 (52), 95 (77), 91 (67), 81 (60), 79 (85).
4.1.1.3. Methyl 3b-hydroxylup-20(29)-en-28-oate (5). To a
solution of compound 2 (150 mg, 0.33 mmol) and anhydrous
K2CO3 (115 mg, 0.83 mmol) in dry DMF (2 ml) was added methyl
iodide (41 ll, 0.66 mmol). The mixture was stirred at room tem-
perature for 1 h. After reaction completion the reaction mixture
was diluted in ethyl acetate (30 ml) and washed with water
(3  20 ml) and brine (20 ml). The organic phase was dried with
anhydrous Na2SO4, filtered and concentrated under reduced
6246 R. C. Santos et al. / Bioorg. Med. Chem. 17 (2009) 6241–6250pressure to give a yellowish solid. This solid was crystallized from
methanol to yield compound 5 (129 mg, 83%): IR (film) mmax 3320,
3070, 1720, 1643 cm1; 1H NMR (CDCl3, 300 MHz) d 4.71 (br s, 1H,
H-29a), 4.58 (br s, 1H, H-29b), 3.67 (s, 3H, COOCH3), 3.18 (dd, 1H,
J = 10.9 Hz, J = 4.5 Hz, H-3a) 2.43 (m, 1H, H-19), 1.69 (s, 3H, H-
30), 0.96 (s, 3H), 0.94 (3H), 0.92 (s, 3H), 0.82 (s, 3H), 0.75 (s, 3H);
13C NMR (CDCl3, 75 MHz) d 177.2 (C28), 149.7 (C20), 110.1 (C29),
80.6 (C3); EI-MS m/z (% rel. intensity): 470 (25) M+, 286 (26), 253
(52), 247 (29), 203 (36), 192 (100), 189 (100), 175 (64), 119 (47),
105 (51).
4.1.1.4. Lup-20(29)-en-3b,28-di-yl acetate (6). Details of the
synthesis of this compound were reported previously.54 Compound
6 (373 mg, 89%): IR (film) mmax 3073, 1735, 1642, 1241, 880 cm1;
1H NMR (CDCl3, 300 MHz) d 4.69 (br s, 1H, H-29a) 4.59 (br s, 1H, H-
29b), 4.47 (dd, J = 10.3 Hz, J = 5.8 Hz, 1H, H-3a), 4.25 (d, J = 11.1 Hz,
1H, H-28a), 3.85 (d, J = 11.1 Hz, 1H, H-28b), 2.45 (dt, J = 10.9 Hz,
J = 5.8 Hz, 1H, H-19), 2.07 (s, 3H, OCOCH3), 2.04 (s, 3H, OCOCH3),
1.68 (s, 3H, H-30), 1.03 (s, 3H), 0.97 (s, 3H), 0.84 (s, 6H), 0.83 (s,
3H); 13C NMR (CDCl3, 75 MHz) d 171.6 (OCOCH3), 171.0 (OCOCH3),
150.1 (C20), 109.9 (C29), 80.9 (C3), 62.8 (C28); EI-MS m/z (% rel.
intensity): 526 (5) M+, 466 (72), 216 (46), 203 (47), 202 (44), 190
(53), 189 (100), 187 (68), 119 (47), 91 (51).
4.1.1.5. 30-Methoxylup-20-(29)-en-3b,28-diol (7) and 30-
bromolup-20(29)-en-3b,28-diol (8). Details of the synthesis of
these compounds were reported previously.31 Compound 7
(1.4 g, 64%): IR (film) mmax 3347, 3073, 1645 cm1; 1H NMR (CDCl3,
300 MHz) d 4.92 (s, 1H, H-29a), 4.91 (s, 1H, H-29b), 3.86 (br s, 2H,
H-30), 3.78 (d, J = 10.5 Hz, 1H, H-28a), 3.35 (s, 3H, OCH3), 3.31 (d,
J = 10.5 Hz, 1H, H-28b), 3.18 (dd, J = 10.8 Hz, J = 5.2 Hz, 1H, H-3a),
2.28 (dt, J = 10.8 Hz, J = 5.4 Hz, 1H, H-19) 1.02 (s, 3H), 0.98 (s,
3H), 0.97 (s, 3H), 0.82 (s, 3H), 0.76 (s, 3H); 13C NMR (CDCl3,
75 MHz) d 150.9 (C20), 109.0 (C29), 78.9 (C3), 74.8 (C30), 60.2
(C28), 58.3 (OCH3); EI-MS m/z (% rel. intensity): 473 (25) M+, 201
(93), 189 (86), 187 (100), 145 (75), 131 (66), 121 (71), 119 (73),
95 (66), 81 (69). Compound 8 (451 mg, 18%): IR (film) mmax 3371,
3075, 1642 cm1; 1H NMR (CDCl3, 300 MHz) d 5.12 (s, 1H, H-
29a), 5.03 (s, 1H, H-29b), 3.99 (s, 2H, H-30), 3.81 (d, J = 10.8 Hz,
1H, H-28a), 3.33 (d, J = 10.8 Hz, 1H, H-28b), 3.19 (dd, J = 10.9 Hz,
J = 5.1 Hz, 1H, H-3a), 2.39 (dt, J = 11.0 Hz, J = 5.3 Hz, 1H, H-19)
1.03 (s, 3H), 0.99 (s, 3H), 0.97 (s, 3H), 0.82 (s, 3H), 0.76 (s, 3H);
13C NMR (CDCl3, 75 MHz) d 151.0 (C20), 109.8 (C29), 78.9 (C3),
60.3 (C28). EI-MS m/z (% rel. intensity): 522 (3) M+, 121 (74), 119
(91), 107 (85), 105 (82), 93 (84), 91 (91), 81 (84), 79 (100), 67 (82).
4.1.1.6. 3b,28-Dihydroxy-(20R)-lupan-29-al (9) and 3b,28-dihy-
droxy-(20S)-lupan-29-al (10). Details of the synthesis of these
compounds were reported previously.55,58 Compound 9 (354 mg,
39%): IR (film) mmax 3393, 1714 cm1; 1H NMR (CDCl3, 300 MHz)
d 9.86 (d, J = 2.0 Hz, 1H, H-29), 3.77 (d, J = 10.8 Hz, 1H, H-28a),
3.26 (d, J = 10.8 Hz, 1H, H-28b), 3.20 (dd, J = 10.9 Hz, J = 5.1 Hz,
1H, H-3a) 2.60 (m, 1H, H-20), 1.10 (d, J = 6.9 Hz, 3H, H-30), 1.03
(s, 3H), 0.98 (s, 3H), 0.95 (s, 3H), 0.84 (s, 3H), 0.77 (s, 3H); 13C
NMR (CDCl3, 75 MHz) d 206.8 (CHO), 78.9 (C3), 60.2 (C28); EI-MS
m/z (% rel. intensity): 458 (2) M+, 369 (100), 207 (43), 192 (51),
189 (72), 161 (67), 133 (31), 121 (31), 107 (36), 95 (33). Compound
10 (179 mg, 20%): IR (film) mmax 3340, 1716 cm1; 1H NMR (CDCl3,
300 MHz) d 9.62 (s, 1H, H-29), 3.80 (d, J = 10.8 Hz, H-28a), 3.33 (d,
J = 10.8 Hz, 1H, H-28b), 3.20 (dd, J = 10.9 Hz, J = 5.1 Hz, 1H, H-3a),
2.65 (m, 1H, H-20), 1.06 (s, 3H), 1.04 (d, J = 7.0 Hz, 3H, H-30),
0.98 (s, 6H), 0.84 (s, 3H), 0.77 (s, 3H); 13C NMR (CDCl3, 75 MHz) d
204.8 (CHO), 78.9 (C3), 60.2 (C28); EI-MS m/z (% rel. intensity):
458 (4) M+, 369 (76), 207 (48), 190 (46), 189 (100), 161 (70), 119
(51), 105 (46), 95 (47), 91 (59).4.1.1.7. 3-Oxolup-20(29)-en-28-oic acid (11). Details of the syn-
thesis of this compound were reported previously.4 Compound 11
(685 mg, 67%): IR (film) mmax 3070, 1703, 1686, 1642 cm1; 1H
NMR (CDCl3, 300 MHz) d 4.77 (br s, 1H, H-29a), 4.64 (br s, 1H, H-
29b), 3.04 (dt, J = 10.7 Hz, J = 4.3 Hz, 1H, H-19), 1.72 (s, 3H, H-30),
1.09 (s, 3H), 1.04 (s, 3H), 1.02 (s, 3H), 0.99 (s, 3H), 0.95 (s, 3H); 13C
NMR (CDCl3, 75 MHz) d 218.2 (C3), 182.2 (C28), 150.3 (C20), 109.7
(C29); EI-MS m/z (% rel. intensity): 454 (19) M+, 408 (24), 393 (20),
248 (85), 189 (100), 175 (62), 133 (55), 119 (76), 105 (69), 79 (52).
4.1.1.8. 3-Oxolup-1,20(29)-dien-28-oic acid (12). A solution of
compound 11 (400 mg, 0.88 mmol) and DDQ (597 mg, 2.64 mmol)
in anhydrous dioxane (18 ml) was heated under reflux and N2
atmosphere for 15 h. After the reaction mixture was diluted in
ethyl acetate (60 ml) and the insoluble matter was removed by fil-
tration. The filtrate was washed with saturated solution of Na2CO3
(3  30 ml), and then with water (30 ml) and brine (30 ml), dried
with anhydrous Na2SO4, filtered and concentrated under reduced
pressure to give a yellowish solid. This solid was submitted to
FCC with petroleum ether 40–60 C/ethyl acetate (4:1) to afford
compound 12 (179 mg, 45%); IR (film) mmax 3070, 1730, 1689,
1645 cm1; 1H NMR (CDCl3, 400 MHz) d 7.11 (d, J = 10.3 Hz, 1H,
H-1), 5.80 (d, J = 10.3 Hz, 1H, H-2), 4.76 (s, 1H, H-29a), 4.63 (s,
1H, H-29b), 3.03 (m, 1H, H-19), 1.70 (s, 3H, H-30), 1.13 (s, 3H),
1.07 (s, 3H), 1.06 (s, 3H), 1.02 (s, 3H), 0.99 (s, 3H); 13C NMR (CDCl3,
100 MHz) d 205.9 (C3), 181.7 (C28), 160.1 (C1), 150.2 (C20), 125.1
(C2), 109.9 (C29); EI-MS m/z (% rel. intensity): 452 (17) M+, 213
(100), 150 (39), 137 (34), 95 (31), 91 (42), 81 (36), 79 (41), 77
(29), 67 (34).
4.1.1.9. 2-Hydroxy-3-oxolup-1,20(29)-dien-28-oic acid
(13). Details of the synthesis of these compounds were reported
previously.57 Compound 13 (273 mg, 73%): mmax 3389, 3073, 1730,
1698, 1669, 1645 cm1; 1H NMR (CDCl3, 300 MHz) d 6.45 (s, 1H, H-
1), 4.75 (s, 1H, H-29a), 4.64 (s, 1H, H-29b), 3.02 (m, 1H, H-19), 1.70
(s, 3H, H-30), 1.20 (s, 3H), 1.13 (s, 3H), 1.10 (s, 3H), 1.00 (s, 3H),
0.98 (s, 3H); 13C NMR (CDCl3, 75 MHz) d 201.2 (C3), 182.4 (C28),
150.1 (C20), 143.9 (C2), 128.9 (C1), 109.9 (C29); EI-MS m/z (% rel.
intensity): 469 (11) M+, 321 (43), 213 (100), 189 (32), 150 (45),
136 (29), 91 (63), 80 (34), 75 (54), 69 (65).
4.1.1.10. 3b-Hydroxy-lup-20(29)-en-28-yl-1H-imidazole-1-car-
boxylate (14) and lup-20(29)-en-3b,28-di-yl-(1H-imidazole-1-
carboxylate) (15). To a solution of compound 1 (200 mg,
0.45 mmol) in anhydrous THF (8 ml), CDI (219 mg, 1.35 mmol)
was added. After 7 h under magnetic stirring at reflux temperature
and N2 atmosphere, the reaction was completed as verified by TLC
control. The reaction mixture was poured onto water (30 ml) and
extracted with diethyl ether (3  30 ml). The combined organic ex-
tract was then washed with water (30 ml), and brine (30 ml), dried
with anhydrous Na2SO4, filtered and concentrated under reduced
pressure to give a yellowish solid. This solid was submitted to
FCC with petroleum ether 40–60 C/ethyl acetate (3:2) and affor-
ded compound 14 (152 mg, 63%): mp (acetone) 202–204 C; IR
(film) mmax 3570, 3078, 1751, 1645, 880 cm1; 1H NMR (CDCl3,
300 MHz) d 8.26 (s, 1H, H-20), 7.46 (br s, 1H, H-50), 7.13 (br s, 1H,
H-40), 4.72 (d, J = 1.4 Hz, 1H, H-29a), 4.67–4,63 (m, 2H, H-28a and
H-29b), 4.21 (d, J = 10.7 Hz, 1H, H-28b), 3.19 (dd, J = 10.8 Hz,
J = 5.2 Hz, 1H, H-3a), 2.47 (dt, J = 10.7 Hz, J = 5.6 Hz, 1H, H-19),
1.70 (s, 3H, H-30), 1.06 (s, 3H), 1.01 (s, 3H), 0.97 (s, 3H), 0.83 (s,
3H), 0.76 (s, 3H); 13C NMR (CDCl3, 75 MHz) d 149.5 (C20), 148.7
(OCO), 136.8 (C20), 129.6 (C40), 117.2 (C50), 110.3 (C29), 78.9 (C3),
67.5 (C28); EI-MS m/z (% rel. intensity): 536 (12) M+, 207 (36),
189 (39), 187 (54), 119 (44), 107 (34), 105 (34), 91 (46), 79 (38),
69 (100) and compound 15 (56 mg, 20%): mp (acetone/n-hexane)
161–163 C; IR (film) mmax 3070, 1757, 1642, 880 cm1; 1H NMR
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7.45 (s, 2H, H-50 and H-50 0), 7.12 (s, 2H, H-40 and H-40 0), 4.73–4.64
(m, 4H, H-3a, H-28a, H-29a and H-29b), 4.20 (d, J = 10.7 Hz, 1H,
H-28b), 2.48 (m, 1H, H-19), 1.71 (s, 3H, H-30), 1.08 (s, 3H), 1.02
(s, 3H), 0.96 (s, 6H), 0.91 (s, 3H); 13C NMR (CDCl3, 75 MHz): d
149.4 (C20), 148.9 (OCO), 148.2 (OCO), 136.8 and 136.7 (C20,
C20 0), 130.0 and 129.5 (C40, C40 0), 117.2 and 117.1 (C50, C50 0), 110.3
(C29), 86.8 (C3), 67.3 (C28); EI-MS m/z (% rel. intensity): 630 (2)
M+, 189 (67), 187 (73), 119 (72), 105 (80), 95 (65), 93 (56), 91
(84), 79 (60), 69 (100).
4.1.1.11. 28-Hydroxy-lup-20(29)-en-3b-yl-1H-imidazole-1-car-
boxylate (16). A solution of compound 1 (200 mg, 0.45 mmol)
and CDI (365 mg, 2.25 mmol) in anhydrous THF (8 ml) was re-
fluxed for 9 h to afford compound 15. Silica gel (200 mg) was
added and this mixture was stirred at room temperature for
18 h. The solid was filtered off and the filtrate was poured onto
water (30 ml) and extracted with diethyl ether (3  30 ml). The or-
ganic phase was then washed with water (30 ml), and brine
(30 ml), dried with Na2SO4, filtered and evaporated to dryness.
The crude product was purified by FCC eluting with petroleum
ether 40–60 C/ethyl acetate (3:2) to yield compound 16
(166 mg, 68%): mp (acetone/n-hexane) 198–199 C; IR (film) mmax
3327, 3070, 1758, 1645, 882 cm1; 1H NMR (CDCl3, 300 MHz) d
8.29 (s, 1H, H-20), 7.47 (s, 1H, H-50), 7.15 (s, 1H, H-40), 4.73–4.69
(m, 2H, H-3a and H-29a), 4.59 (m, 1H, H-29b), 3.80 (d, J = 10.7 Hz,
1H, H-28a), 3.34 (d, J = 10.7 Hz, 1H, H-28b), 2.40 (dt, J = 10.7 Hz,
J = 5.7 Hz, 1H, H-19), 1.69 (s, 3H, H-30), 1.04 (s, 3H), 0.99 (s, 3H),
0.96 (s, 3H), 0.95 (s, 3H), 0.89 (s, 3H); 13C NMR (CDCl3, 75 MHz) d
150.4 (C20), 147.9 (OCO), 136.6 (C20), 128.9 (C40), 117.4 (C50),
109.7 (C29), 87.1 (C3), 60.4 (C28); EI-MS m/z (% rel. intensity):
536 (6) M+, 203 (37), 189 (35), 119 (41), 105 (37), 95 (35), 91
(30), 81 (29), 79 (32), 69 (100).
4.1.1.12. 3b-(1H-Imidazole-1-carbonyloxy)-lup-20(29)-en-28-
oic acid (17) and 28-(1H-imidazol-1-yl)-28-oxo-lup-20(29)-en-
3b-yl-1H-imidazole-1-carboxylate (18). The method followed
that described for compound 14 but using compound 2 (297 mg,
0.65 mmol) and CDI (527 mg, 3.25 mmol) in anhydrous THF
(12 ml) at reflux for 7 h. The resulting yellowish solid was purified
by FCC using petroleum ether 40–60 C/ethyl acetate (2:3) to af-
ford compound 17 (249 mg, 70%): mp (acetone/n-hexane) 228–
230 C; IR (film) mmax 3070, 1762, 1699, 1642 cm1; 1H NMR
(CDCl3, 300 MHz) d 8.21 (s, 1H, H-20), 7.43 (s, 1H, H-50), 7.12 (s,
1H, H-40), 4.75 (br s, 1H, H-29a), 4.69 (dd, J = 10.1 Hz, J = 6.2 Hz,
1H, H-3a), 4.62 (br s, 1H, H-29b), 3.04 (dt, J = 10.7 Hz, J = 4.1 Hz,
1H, H-19), 1.70 (s, 3H, H-30), 0.99 (s, 3H), 0.96–0.95 (m, 9H),
0.89 (s, 3H); 13C NMR (CDCl3, 75 MHz) d 181.5 (C28), 150.5 (C20),
148.3 (OCO), 136.9 (C20), 129.8 (C40), 117.2 (C50), 109.7 (C29),
86.6 (C3); EI-MS m/z (% rel. intensity): 550 (4) M+, 203 (41), 189
(50), 187 (40), 175 (42), 159 (37), 119 (47), 91 (41), 79 (36), 69
(100) and compound 18 (88 mg, 23%): mp (acetone/n-hexane)
150–151 C; IR (film) mmax 3073, 1757, 1722, 1642 cm1; 1H NMR
(CDCl3, 400 MHz) d 8.28 (s, 1H, H20), 8.13 (s, 1H, H20 0), 7.53 (s,
1H, H-50), 7.41 (s, 1H, H-50 0), 7.07 (s, 1H, H-40 0) 7.05 (s, 1H, H-40),
4.78 (br s, 1H, H-29a), 4.69–4.66 (m, 2H, H-3a, H-29b), 2.97 (dt,
J = 10.9 Hz, J = 4.5 Hz, 1H, H-19), 1.72 (s, 3H, H-30), 1.01 (s, 3H),
0.95 (s, 9H), 0.91 (s, 3H); 13C NMR (CDCl3, 100 MHz) d 172.9
(C28) 149.7 (C20), 148.5 (OCO), 137.3 (C20), 137.0 (C20 0), 130.5
(C40 0), 129.6 (C40), 117.4 (C50), 117.0 (C50 0), 110.2 (C29), 86.3 (C3);
EI-MS m/z (% rel. intensity): 600 (4) M+, 393 (33), 203 (22), 189
(31), 107 (27), 105 (27), 95 (38), 91 (28), 81 (24), 69 (100).
4.1.1.13. 28-Acetoxy-lup-20(29)-en-3b-yl-1H-imidazole-1 car-
boxylate (19). The method followed that described for compound
14 but using compound 3 (242 mg, 0.5 mmol) and CDI (162 mg,1 mmol) in anhydrous THF (10 ml) at reflux for 7 h. The resulting
white solid was purified by FCC using petroleum ether 40–60 C/
ethyl acetate (4:1) to afford compound 19 (235 mg, 81%): mp (ace-
tone/n-hexane) 194–195 C; IR (film) mmax 3070, 1756, 1733, 1642,
1239, 882 cm1; 1H NMR (CDCl3, 400 MHz) d 8.12 (s, 1H, H-20), 7.41
(s, 1H, H-50), 7.07 (s, 1H, H-40), 4.70–4.66 (m, 2H, H-3a and H-29a)
4.60 (s, 1H, H-29b), 4.26 (d, J = 11.0 Hz, 1H, H-28a), 3.85 (d,
J = 11.0 Hz, 1H, H-28b), 2.45 (dt, J = 10.8 Hz, J = 5.9 Hz, 1H, H-19),
2.07 (s, 3H, OCOCH3), 1.69 (s, 3H, H-30), 1.05 (s, 3H), 0.99 (s, 3H),
0.95 (s, 6H), 0.89 (s, 3H); 13C NMR (CDCl3, 100 MHz) d 171.6
(OCOCH3), 150.0 (C20), 148.5 (OCO), 137.0 (C20), 130.5 (C40),
117.0 (C50), 109.9 (C29), 86.3 (C3), 62.8 (C28); EI-MS m/z (% rel.
intensity): 578 (5), M+, 189 (64), 187 (56), 145 (44), 133 (43),
119 (51), 105 (66), 95 (50), 91 (71), 69 (100).
4.1.1.14. 3b-Acetoxy-lup-20(29)-en-28-yl-1H-imidazole-1-car-
boxylate (20). The method followed that described for compound
14 but using compound 4 (242 mg, 0.5 mmol) and CDI (162 mg,
1 mmol) in anhydrous THF (10 ml) at reflux for 5 h. The resulting
white solid was purified by FCC using petroleum ether 40–60 C/
ethyl acetate (4:1) to afford compound 20 (247 mg, 85%): mp (ace-
tone/n-hexane) 101–103 C; IR (film) mmax 3073, 1760, 1730, 1642,
1240, 882 cm1; 1H NMR (CDCl3, 300 MHz) d 8.22 (s, 1H, H-20), 7.45
(s, 1H, H-50), 7.12 (s, 1H, H-40), 4.72 (br s, 1H, H-29a), 4.67–4.63 (m,
2H, H-28a and H-29b), 4.47 (dd, J = 10.2 Hz, J = 5.8 Hz, 1H, H-3a),
4.20 (d, J = 10.6 Hz, 1H, H-28b), 2.48 (m, 1H, H-19), 2.05 (s, 3H,
OCOCH3), 1.71 (s, 3H, H-30), 1.06 (s, 3H), 1.00 (s, 3H), 0.86 (s,
3H), 0.85 (s, 3H), 0.84 (s, 3H); 13C NMR (CDCl3, 75 MHz) d 170.9
(OCOCH3), 149.5 (C20), 148.8 (OCO), 136.8 (C20), 129.9 (C40),
117.2 (C50), 110.3 (C29), 80.8 (C3), 67.4 (C28); EI-MS m/z (% rel.
intensity): 578 (19) M+, 189 (24), 187 (26), 133 (20), 119 (35),
105 (36), 93 (19), 91 (42), 79 (26), 69 (100).
4.1.1.15. Methyl 3b-(1H-imidazole-1-carbonyloxy)-lup-20(29)-
en-28-oate (21). The method followed that described for com-
pound 14 but using compound 5 (100 mg, 0.2 mmol) and CDI
(65 mg, 0.4 mmol) in anhydrous THF (4 ml), at reflux for 6 h. The
crude product was purified by FCC eluting with petroleum ether
40-60 C/ethyl acetate (3:2) to yield compound 21 (105 mg, 88%):
mp (acetone/n-hexane) 220–224 C; IR (film) mmax 3070, 1758,
1725, 1642, 1240 cm1; 1H NMR (CDCl3, 300 MHz) d 8.24 (s, 1H,
H20), 7.45 (s, 1H, H-50), 7.13 (s, 1H, H-40), 4.74–4.67 (m, 2H, H-3a,
H-29a), 4.61 (br s, 1H, H-29b), 3.67 (s, 3H, COOCH3), 3.00 (dt,
J = 10.3 Hz, J = 3.7 Hz, 1H, H-19), 1.69 (s, 3H, H-30), 0.97 (s, 3H),
0.95 (s, 6H), 0.93 (s, 3H), 0.89 (s, 3H); 13C NMR (CDCl3, 75 MHz) d
176.6 (C28), 150.5 (C20), 148.1 (OCO), 136.6 (C20), 129.3 (C40),
117.2 (C50), 109.6 (C29), 86.9 (C3); EI-MS m/z (% rel. intensity):
564 (4) M+, 203 (35), 190 (28), 189 (71), 187 (38), 175 (35), 119
(43), 105 (33), 91 (37), 79 (33), 69 (100).
4.1.1.16. 3b-Hydroxy-30-methoxylup-20(29)-en-28-yl-1H-imid-
azole-1-carboxylate (22) and 30-methoxylup-20(29)-en-3b,28-
di-yl-(1H-imidazole-1-carboxylate) (23). The method followed
that described for compound 14 but using compound 7 (213 mg,
0.45 mmol) and CDI (219 mg, 1.35 mmol) in anhydrous THF (8 ml),
at reflux for 8 h. The resultingwhite solidwaspurifiedbyFCCeluting
with petroleum ether 40–60 C/ethyl acetate (1:1) to afford com-
pound 22 (174 mg, 68%): mp (acetone/n-hexane) 136–138 C; IR
(film) mmax 3406, 3078, 1760, 1645, 1239 cm1; 1H NMR (CDCl3,
300 MHz) d 8.23 (s, 1H, H-20), 7.47 (s, 1H, H-50), 7.13 (s, 1H, H-40),
4.98 (s, 1H, H-29a), 4.95 (s, 1H, H-29b), 4.65 (d, J = 10.8 Hz, 1H, H-
28a), 4.21 (d, J = 10.8 Hz, 1H, H-28b), 3.89 (s, 2H, H-30), 3.38 (s, 3H,
OCH3), 3.20 (dd, J = 10.8 Hz, J = 5.1 Hz, 1H, H-3a), 2.39 (dt,
J = 11.0 Hz, J = 5.3 Hz, 1H, H-19), 1.07 (s, 3H), 1.02 (s, 3H), 0.98 (s,
3H), 0.84 (s, 3H), 0.78 (s, 3H); 13C NMR (CDCl3, 75 MHz) d 150.3
(C20), 148.8 (OCO), 136.8 (C20), 129.9 (C40), 117.2 (C50), 109.7
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intensity): 566 (7) M+, 187 (30), 119 (34), 105 (32), 93 (32), 91 (46),
81 (33), 79 (39), 69 (100), 67 (29) and compound 23 (83 mg, 28%):
mp (acetone/n-hexane) 174–176 C; IR (film) mmax 3078, 1757,
1645, 1239 cm1; 1H NMR (CDCl3, 400 MHz) d 8.15 (s, 1H, H-20),
8.13 (s, 1H, H-20 0), 7.43 (s, 1H, H-50), 7.41 (s, 1H, H-50 0), 7.08 (s, 1H,
H-40), 7.07 (s, 1H, H-40 0), 4.98 (s, 1H, H-29a), 4.95 (s, 1H, H-29b),
4.70–4.62 (m, 2H, H-3a, H-28a), 4.18 (d, J = 10.7 Hz, 1H, H-28b),
3.89 (s, 2H, H-30), 3.37 (s, 3H, OCH3), 2.40 (dt, J = 11.0 Hz,
J = 5.3 Hz, 1H, H-19), 1.09 (s, 3H), 1.03 (s, 3H), 0.96 (s, 6H), 0.91 (s,
3H); 13C NMR (CDCl3, 100 MHz) d 150.4 (C20), 149.1 (OCO), 148.5
(OCO), 137.0 (C20, C20 0), 130.7 and 130.6 (C40, C40 0), 117.0 (C50, C50 0),
109.9 (C29), 86.2 (C3), 75.1 (C30), 66.9 (C28), 58.4 (OCH3); EI-MS
m/z (% rel. intensity): 660 (11) M+, 199 (23), 189 (25), 187 (30), 145
(28), 143 (20), 119 (22), 105 (21), 91 (34), 69 (100).
4.1.1.17. 3b-Hydroxy-(20R)-lupan-29-oxo-28-yl-1H-imidazole-
1-carboxylate (24) and (20R)-lupan-29-oxo-3b,28-di-yl-(1H-
imidazole-1-carboxylate) (25). The method followed that de-
scribed for compound 14 but using compound 9 (298 mg,
0.65 mmol) and CDI (316 mg, 1.95 mmol) in anhydrous THF
(12 ml), at reflux for 7 h. The resulting white solid was purified
by FCC eluting with petroleum ether 40–60 C/ethyl acetate (2:3)
to afford compound 24 (239 mg, 67%): mp (acetone/n-hexane)
175–177 C; IR (film) mmax 3414, 1762, 1722, 1239 cm1; 1H NMR
(CDCl3, 400 MHz) d 9.85 (d, J = 1.9 Hz, 1H, H-29), 8.15 (br s, 1H,
H-20), 7.42 (br s, 1H, H-50), 7.09 (br s, 1H, H-40), 4.60 (d,
J = 10.9 Hz, 1H, H-28a), 4.13 (d, J = 10.9 Hz, 1H, H-28b), 3.21 (dd,
J = 10.8 Hz, J = 5.1 Hz, 1H, H-3a), 2.64 (m, 1H, H-20), 1.15 (d,
J = 7.0 Hz, 3H, H-30), 1.07 (s, 3H), 0.98 (s, 6H), 0.85 (s, 3H), 0.77
(s, 3H); 13C NMR (CDCl3, 100 MHz) d 206.3 (C29), 149.1 (OCO),
137.0 (C20), 130.6 (C40), 117.1 (C50), 78.8 (C3), 66.4 (C28), 48.8
(C20), 14.4 (C30); EI-MS m/z (% rel. intensity): 552 (18) M+, 207
(46), 189 (58), 187 (47), 145 (49), 119 (45), 105 (51), 91 (58), 79
(48), 69 (100) and compound 25 (128 mg, 30%): mp (acetone/n-
hexane) 145–146 C; IR (film) mmax 1758, 1716, 1239 cm1; 1H
NMR (CDCl3, 300 MHz) d 9.85 (d, J = 1.9 Hz, 1H, H-29), 8.15 (br s,
2H, H-20, H-20 0), 7.43 (br s, 2H, H-50, H-50 0), 7.09 (br s, 2H, H-40, H-
40 0), 4.69 (dd, J = 10.9 Hz, J = 5.4 Hz, 1H, H-3a), 4.61 (d, J = 10.9 Hz,
1H, H-28a), 4.13 (d, J = 10.9 Hz, 1H, H-28b), 2.64 (m, 1H, H-20),
1.16 (d, J = 7.0 Hz, 3H, H-30), 1.09 (s, 3H), 0.99 (s, 3H), 0.97 (s,
6H), 0.92 (s, 3H); 13C NMR (CDCl3, 75 MHz) d 206.1 (C29), 148.9
(OCO), 148.4 (OCO) 136.9 (C20, C20 0), 130.6 (C40, C40 0), 117.0 (C50,
C50 0), 86.2 (C3), 66.3 (C28); EI-MS m/z (% rel. intensity): 646 (6)
M+, 187 (23), 159 (23), 119 (23), 105 (29), 93 (20), 91 (34), 81
(19), 79 (22), 69 (100).
4.1.1.18. 28-(1H-Imidazol-1-yl)-lup-20(29)-en-3,28-dione (26).
The method followed that described for compound 14 but using
compound 11 (205 mg, 0.45 mmol) and CDI (219 mg, 1.35 mmol)
in anhydrous THF (8 ml), at reflux for 9 h. The crude product was
purified by FCC eluting with petroleum ether 40–60 C/ethyl ace-
tate (3:2) to yield compound 26 (203 mg, 89%): mp (benzene)
189–190 C; IR (film) mmax 3073, 1721, 1703, 1642 cm1; 1H NMR
(CDCl3, 400 MHz) d 8.28 (s, 1H, H-20), 7.54 (s, 1H, H-50), 7.05 (s,
1H, H-40), 4.78 (s, 1H, H-29a), 4.65 (s, 1H, H-29b), 2.97 (dt,
J = 10.7 Hz, J = 4.2 Hz, 1H, H-19), 1.71 (s, 3H, H-30), 1.06 (s, 3H),
1.01 (br s, 6H), 0.96 (s, 3H), 0.94 (s, 3H); 13C NMR (CDCl3,
100 MHz) d 217.9 (C3), 172.9 (C28), 149.7 (C20), 137.3 (C20),
129.6 (C40), 117.4 (C50), 110.2 (C29); EI-MS m/z (% rel. intensity):
504 (4) M+, 410 (30), 409 (100), 245 (46), 203 (49), 189 (58), 147
(25), 107 (31), 105 (27), 91 (24).
4.1.1.19. 28-(1H-Imidazol-1-yl)-lup-1,20(29)-dien-3,28-dione
(27). The method followed that described for compound 14 but
using compound 12 (204 mg, 0.45 mmol) and CDI (219 mg,1.35 mmol) in anhydrous THF (8 ml), at reflux for 9 h. The crude
product was purified by FCC eluting with petroleum ether 40–
60 C/ethyl acetate (3:2) to yield compound 27 (186 mg, 82%):
mp (acetone/n-hexane) 95–96 C; IR (film) mmax 3070, 1762,
1720, 1668, 1645 cm1; 1H NMR (CDCl3, 400 MHz) d 8.29 (s, 1H,
H-20), 7.54 (s, 1H, H-50), 7.12 (d, J = 10.1 Hz, 1H, H-1), 7.05 (s, 1H,
H-40), 5.80 (d, J = 10.1 Hz, 1H, H-2), 4.79 (s, 1H, H-29a), 4.67 (s,
1H, H-29b), 2.98 (dt, J = 11.0 Hz, J = 4.6 Hz, 1H, H-19), 1.72 (s, 3H,
H-30), 1.12 (s, 3H), 1.07 (s, 6H), 1.01 (s, 3H), 1.00 (s, 3H); 13C
NMR (CDCl3, 100 MHz) d 205.4 (C3), 172.6 (C28), 159.6 (C1),
149.5 (C20), 137.1 (C20), 128.8 (C40), 125.2 (C2), 117.5 (C50),
110.3 (C29); EI-MS m/z (% rel. intensity): 502 (4) M+, 408 (32),
407 (100), 243 (43), 205 (30), 203 (26), 189 (34), 135 (25), 105
(28), 91 (29).
4.1.1.20. 2-Hydroxy-28-(1H-imidazol-1-yl)-lup-1,20(29)-dien-
3,28-dione (28) and 28-(1H-imidazole-1-yl)-3,28-dioxo-lup-
1,20(29)-dien-2-yl-1H-imidazole-1-carboxylate (29). The meth-
od followed that described for compound 14 but using compound
13 (304 mg, 0.65 mmol) and CDI (524 mg, 3.25 mmol) in anhy-
drous THF (12 ml), at reflux for 8 h. The resulting white solid was
purified by FCC eluting with petroleum ether 40–60 C/ethyl ace-
tate (1:4) to afford compound 28 (237 mg, 70%): mp (acetone/n-
hexane) 145–148 C; IR (film) mmax 3448, 3078, 1762, 1724, 1667,
1645 cm1; 1H NMR (CDCl3, 400 MHz) d 8.43 (s, 1H, H-20), 7.56
(s, 1H, H-50), 7.09 (s, 1H, H-40), 6.45 (s, 1H, H-1), 4.79 (s, 1H, H-
29a), 4.67 (s, 1H, H-29b), 2.97 (dt, J = 10.6 Hz, J = 4.0 Hz, 1H, H-
19), 1.72 (s, 1H, H-30), 1.19 (s, 3H), 1.14 (s, 3H), 1.10 (s, 3H), 0.99
(br s, 6H); 13C NMR (CDCl3, 100 MHz) d 201.1 (C3), 172.9 (C28),
149.5 (C20), 143.9 (C2), 137.3 (C20), 129.6 (C40), 128.8 (C1), 117.4
(C50), 110.4 (C29); EI-MS m/z (% rel. intensity): 518 (22) M+, 423
(100), 215 (94), 213 (65), 189 (57), 119 (55), 105 (54), 91 (89),
79 (54), 69 (55) and compound 29 (109 mg, 27%): mp (acetone/
n-hexane) 211–213 C; IR (film) mmax 3070, 1826, 1757, 1721,
1642 cm1; 1H NMR (CDCl3, 300 MHz) d 8.42 and 8.27 (both s, each
1H, H-20, H-20 0), 7.79 and 7.51 (both s, each 1H, H-50, H-50 0), 7.21
and 7.04 (both s, each 1H, H-40, H-40 0), 6.97 (s, 1H, H-1), 4.74 (br
s, 1H, H-29a), 4.67 (br s, 1H, H-29b), 2.92 (dt, J = 10.9 Hz,
J = 4.6 Hz, 1H, H-19), 1.73 (s, 3H, H-30), 1.36 (s, 3H), 1.17 (s, 3H),
1.16 (s, 3H), 1.00 (s, 3H), 0.89 (s, 3H); 13C NMR (CDCl3, 75 MHz) d
202.3 (C3), 172.8 (C28), 152.2 (C20), 149.1 (OCO), 146.5 (C2),
137.2 (C20 and C20 0), 132.6 (C1), 129.6 (C40 and C40 0), 117.3 (C50
and C50 0), 110.6 (C29); EI-MS m/z (% rel. intensity): 612 (9) M+,
518 (35), 517 (100), 449 (19), 405 (14), 295 (15), 189 (27), 105
(18), 91 (21), 69 (16).
4.2. Antiproliferative activity
4.2.1. General
All cell lines were purchased from the American Type Culture
Collection (ATCC, Rockville, MD). RPMI 1640 medium, Dulbecco’s
Modified Eagle Medium (DMEM—D5796), Dulbecco’s Phosphate
Buffered Saline (DPBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) powder and dimethylsulfoxide
(DMSO) were obtained from Sigma–Aldrich Co. Penicillin/strepto-
mycin (P/S) and L-glutamine were obtained from Gibco-BRL. So-
dium pyruvate and trypsin/EDTA (0.05%/0.02%) were obtained
from Biological Industries. Fetal Bovine Serum (FBS) were pur-
chased from PAA Laboratories and XTT kit was obtained from
Roche.
A-375, HT-29, HeLa, MIA PaCa-2 and SH-SY5Y cells were rou-
tinely maintained in DMEM supplemented with 10% heat-inacti-
vated FBS and 1% P/S solution. HepG2 cells were maintained in
DMEM supplemented with 10% heat-inactivated FBS, 1% P/S and
1 mM of sodium pyruvate. Jurkat cells were grown in RPMI 1640
medium supplemented with 10% heat-inactivated FBS, 1% P/S
R. C. Santos et al. / Bioorg. Med. Chem. 17 (2009) 6241–6250 6249and 2 mM L-glutamine. MCF-7 were maintained in RPMI 1640
medium supplemented with 10% heat-inactivated FBS, 0.2% P/S,
2 mM L-glutamine, 1 mM of sodium pyruvate and 0.1 mg/ml of
insulin.
All cell cultures were incubated at 37 C in 5% CO2 saturated
atmosphere and 99% humidity.
4.2.2. Viability assay
The cell viability of HeLa and HepG2 cells in the presence of the
synthesized compounds was determined by the MTT assay. Briefly,
exponentially growing cells were plated in 96-well plates at a den-
sity of 1  103 and 8  103 cells/well respectively and incubated
for 24 h before treatment. The growth medium was replaced with
one containing either the test compounds dissolved in DMSO (final
DMSO concentration <0.1%) at different concentrations or only
DMSO, in triplicate wells, and cells were incubated for 72 h. After
incubation with the compounds, the medium was removed and
MTT solution (0.5 mg/ml, 100 ll) was added to each well and the
plates were incubated again for 1 h. MTT solution was removed
and DMSO (100 ll) was then added to dissolve the formazan crys-
tals. The plates were immediately read at 550 nm on an ELISA plate
reader (Tecan Sunrise MR20-301, TECAN, Austria).
For Jurkat cells, the cell viability was determined by XTT assay.
Briefly, exponentially growing cells were plated in 96-well plates
at a density of 5.5  103 cells/well, treated with different concen-
trations of compounds or vehicle (medium with DMSO) in tripli-
cate and incubated for 72 h. After incubation with the
compounds the XTT labeling mixture (100 ll) was added to each
of the wells and after a 4 h incubation period the plates were read
at 450 nm on an ELISA plate reader.
Concentrations that inhibit cell growth by 50% (IC50) compared
to non-treated cells were determined by non-linear regression
with Graphpad Prism software version 4.0 (GraphPad Software,
Inc., San Diego, CA). All the IC50 results represent an average of a
minimum of three experiments and were expressed as
means ± standard deviation (SD). Compound 2 was used as a posi-
tive control.
For the screening of antiproliferative activity, cell suspensions
were prepared and diluted according to the particular cell type
and the expected target cell density (1  103–30  103 cells/well
based on the cell growth characteristics). Cells were plated in 96-
well plates and cell viability was determined by the MTT assay
(MCF-7, HepG2, A-375, HT-29, HeLa and MIA PaCa-2) or XTT assay
(Jurkat and SH-SY5Y) after 72 h of incubation with the different
derivatives at the concentration of 20 lM, in triplicate.
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